Xin Lang Cai Jing·2026-02-27 02:55Group 1 - The core viewpoint of the news is that Junshi Biosciences experienced a decline in stock price and significant trading activity, indicating high investor interest and potential volatility in the stock [1] - On February 26, Junshi Biosciences' stock fell by 2.33%, with a trading volume of 303 million yuan, and a net financing purchase of 759.47 million yuan [1] - The total margin balance for Junshi Biosciences reached 1.448 billion yuan, with the financing balance accounting for 5.53% of the circulating market value, indicating a high level of leverage [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs, with 90.67% of its revenue coming from drug sales [2] - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% increase [2] - As of September 30, 2025, the number of shareholders increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2]